Review article: colorectal carcinoma and inflammatory bowel disease - PubMed (original) (raw)
Review
Review article: colorectal carcinoma and inflammatory bowel disease
J Eaden. Aliment Pharmacol Ther. 2004 Oct.
Free article
Abstract
The risk of colorectal cancer for any patient with ulcerative colitis is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. The relative risk of colorectal cancer in Crohn's colitis is approximately 5.6 and should raise the same concerns as in ulcerative colitis. Risk factors for colorectal cancer include disease duration, early onset, extensive disease, primary sclerosing cholangitis and a family history of sporadic colorectal cancer. All patients should have a review colonoscopy 8-10 years after diagnosis to establish the extent of the disease. Surveillance should begin 8-10 years after disease onset for pancolitis and 15-20 years after disease onset for left-sided disease. Regular surveillance is recommended, with a screening interval every 3 years in the second decade of disease and annually by the fourth decade. Random biopsies should be taken at regular intervals with attention paid to dysplasia-associated lesions or masses, irregular plaques, villiform elevations, ulcers and strictures. Dysplasia is recognized as a premalignant condition, but the likelihood of progression to cancer is difficult to predict. High-grade dysplasia, confirmed by two expert gastrointestinal pathologists, is a strong indication for colectomy, as is low-grade dysplasia, although the diagnosis of low-grade dysplasia is unreliable. Surveillance programmes indicate that the overall 5-year survival rate is higher in surveyed patients, although patients still present with Dukes C cancers or disseminated malignancy. Surveillance has huge socioeconomic implications. As surveillance is not 100% effective, alternative ways of reducing the cancer risk with chemopreventive agents, such as aminosalicylates, are being considered.
Similar articles
- Chronic inflammatory bowel disease and cancer.
Pohl C, Hombach A, Kruis W. Pohl C, et al. Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70. Hepatogastroenterology. 2000. PMID: 10690586 Review. - Dysplasia in inflammatory bowel disease.
Greenson JK. Greenson JK. Semin Diagn Pathol. 2002 Feb;19(1):31-7. Semin Diagn Pathol. 2002. PMID: 11936264 Review. - [Pathobiology of dysplasia in chronic inflammatory bowel disease: Current recommendations for surveillance of dysplasia].
Raithel M, Weidenhiller M, Schwab D, Müller S, Hahn EG. Raithel M, et al. Z Gastroenterol. 2001 Oct;39(10):861-75. doi: 10.1055/s-2001-17870. Z Gastroenterol. 2001. PMID: 11605156 Review. German. - Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH. Brackmann S, et al. Scand J Gastroenterol. 2009;44(1):46-55. doi: 10.1080/00365520801977568. Scand J Gastroenterol. 2009. PMID: 18609187 - Carcinogenesis in inflammatory bowel disease.
Herszenyi L, Miheller P, Tulassay Z. Herszenyi L, et al. Dig Dis. 2007;25(3):267-9. doi: 10.1159/000103898. Dig Dis. 2007. PMID: 17827953
Cited by
- Causes of Colectomy in Patients with Ulcerative Colitis: Findings from an Iranian National Registry.
Momayez Sanat Z, Vahedi H, Malekzadeh R, Kasaeian A, Mohammadi Ganjaroudi N, Sima A, Mansour Ghanaei F, Ghadir M, Tirgar Fakheri H, Nasseri Moghaddam S, Alatab S, Sadeghi A, Anushiravani A, Maleki I, Yazdanbod A, Vossoughinia H, Seyyedmajidi M, Naghshbandi SJ, Baniasadi N, Parhizkar B, Matinkhah S, Gheibi S, Hosseini Hemmat Abadi RS, Valizadeh Toosi S. Momayez Sanat Z, et al. Arch Iran Med. 2024 Jul 1;27(7):350-356. doi: 10.34172/aim.28887. Arch Iran Med. 2024. PMID: 39072382 Free PMC article. - How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer.
Majumder A, Bano S. Majumder A, et al. Biomolecules. 2024 May 29;14(6):633. doi: 10.3390/biom14060633. Biomolecules. 2024. PMID: 38927037 Free PMC article. Review. - Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota.
Li J, Ji Y, Chen N, Dai L, Deng H. Li J, et al. Cell Biosci. 2023 Oct 24;13(1):194. doi: 10.1186/s13578-023-01139-8. Cell Biosci. 2023. PMID: 37875976 Free PMC article. Review. - The yield of dysplasia and serrated lesions in a single-centre tertiary inflammatory bowel disease cohort.
Yeaman F, Thin L. Yeaman F, et al. Therap Adv Gastroenterol. 2023 May 3;16:17562848231167280. doi: 10.1177/17562848231167280. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37153500 Free PMC article. - Novel biomarkers for neoplastic progression from ulcerative colitis to colorectal cancer: a systems biology approach.
Shahnazari M, Afshar S, Emami MH, Amini R, Jalali A. Shahnazari M, et al. Sci Rep. 2023 Feb 28;13(1):3413. doi: 10.1038/s41598-023-29344-y. Sci Rep. 2023. PMID: 36854781 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials